SynAct Pharma AB

OM:SYNACT Stock Report

Market Cap: SEK 965.5m

SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SYNACT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders8,861,96618.1%
Institutions9,061,68118.5%
General Public14,850,72330.3%
Private Companies16,234,54833.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.

Top Shareholders

Top 25 shareholders own 70.42% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.8%
NBCD A/S
5,302,732SEK 104.5m33.8%no data
10%
Avanza Fonder AB
4,899,091SEK 96.5m75%0.1%
8.09%
Sanos Bioscience A/S
3,962,790SEK 78.1m0%no data
5.33%
Thomas Jonassen
2,610,032SEK 51.4m684%no data
4.66%
Thomas Ringberg
2,282,729SEK 45.0m1.32%no data
4.5%
Bioinvest Sverige Ab
2,205,401SEK 43.4m0%no data
4.41%
TJ Biotech Invest ApS
2,161,225SEK 42.6m0%no data
3.47%
Nordnet AB (publ), Asset Management Arm
1,698,777SEK 33.5m0%0.51%
3.06%
Ryan Quinn
1,500,000SEK 29.6m0%no data
3.05%
Heights Capital Management, Inc.
1,493,981SEK 29.4m0%no data
2.91%
Quantass Invest Aps
1,428,558SEK 28.1m0%no data
2.4%
Goodwind Holding GmbH
1,173,842SEK 23.1m0%no data
2.28%
Thomas von Koch
1,118,210SEK 22.0m0%no data
1.72%
Torbjorn Bjerke
840,532SEK 16.6m0%no data
1.67%
Handelsbanken Asset Management
818,133SEK 16.1m0%no data
0.65%
SEB Investment Management AB
320,139SEK 6.3m0%no data
0.65%
Niklas Borgquist
320,139SEK 6.3m0%no data
0.29%
FCG Fonder AB
143,121SEK 2.8m0%0.03%
0.16%
James Knight
77,452SEK 1.5m0%no data
0.13%
Terje Kalland
62,855SEK 1.2m0%no data
0.075%
Skandia Fonder AB
36,871SEK 726.3k0%no data
0.038%
Thomas Boesen
18,604SEK 366.5k0%no data
0.028%
Jeppe Ovlesen
13,825SEK 272.4k0%no data
0.025%
Storebrand Fonder AB,
12,469SEK 245.6k0%no data
0.02%
Bjorn Westberg
10,000SEK 197.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 14:34
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Markets
Carl RamaniusRedeye